How Long Do Allergy Shots Take to Work? SCIT vs. SLIT Onset Compared

The honest answer has two parts: immunologically, SCIT may produce a faster IgG4 peak due to higher per-dose allergen load, with a slight advantage at 6 months observed in some studies (Chelladurai et al., 2013 meta-analysis). In real-world practice, however, SLIT often achieves a faster practical time-to-benefit because it starts immediately at home without the scheduling delays, appointment wait times, and 8-28 week build-up that SCIT requires before reaching the therapeutic maintenance dose. The functional gap narrows considerably at 12 months: the best head-to-head and network meta-analysis data (Nelson, J Allergy Clin Immunol Pract 2015; Tie, Laryngoscope 2022) show no statistically significant difference in efficacy between SCIT and approved SLIT products for grass pollen at 12 months. The choice of modality should therefore focus primarily on safety, convenience, and adherence likelihood rather than speed differences alone.

For seasonal allergens like grass pollen, ragweed, or tree pollen, first-season improvement depends on where you are in treatment when your allergy season begins. Patients who start SCIT well before their relevant season and complete build-up before peak exposure typically see approximately 30% symptom reduction in their first treated season (Calderon et al., Cochrane 2007). Patients who start during or close to the season may experience minimal benefit in year 1 because their build-up is still ongoing. Second-season results are more reliably meaningful: 50-70% symptom reduction is the range reported in meta-analyses. Patients who start SCIT during or immediately before the season are often advised to reduce doses during peak season (approximately 40% of US practices do this per Larenas-Linnemann 2012) to reduce reaction risk, which can slow dose escalation and push perceived benefit further into year 2.

Allergy shots work through genuine immune system reprogramming — not suppression or symptom blocking — which is biologically slow. The process requires instructing allergen-specific T cells (which were primed toward an allergic Th2 phenotype over years of allergen exposure) to shift toward a regulatory, tolerant phenotype. This T-cell re-education requires sustained, repeated allergen exposure over months before a meaningful population of regulatory T cells is established. Concurrently, B cells must be redirected from IgE to IgG4 antibody production — a process that takes months of repeated allergen stimulation to produce clinically relevant IgG4 levels. These fundamental immunologic constraints are why the timeline is measured in months rather than days. No drug can reliably accelerate this process without compromising safety; the timeline reflects the speed of genuine immune adaptation, not a limitation of the treatment.

Twelve months at therapeutic maintenance dose without perceivable benefit is the threshold at which AAAAI Practice Parameters recommend formal reassessment rather than simply continuing and waiting longer. The evaluation should address the most common causes of suboptimal response: subtherapeutic dosing (each major allergen in the maintenance dose needs to reach approximately 5-20 micrograms per injection); allergen mismatch (the vial may contain allergens that do not match your actual clinical triggers); ongoing high allergen exposure at home that overwhelms incremental immune tolerance; and the possibility of new sensitizations not in the current treatment vial. If dosing, allergen selection, and environmental factors have all been optimized and there is still no IgG4 rise by 12 months, non-responder status should be formally considered and alternative approaches — including modality switch — discussed. Continuing injections at unchanged dose and allergen mix after 12 months of documented non-response is not supported by AAAAI guidelines.

Not necessarily, but managing expectations around the first treated season is important. Patients who complete build-up well before their relevant pollen season and achieve full maintenance dose before peak exposure typically see their best first-season results — approximately 30% symptom reduction on average. Patients who start mid-season or whose build-up extends into the season may experience minimal first-season benefit. The good news: second-season results are consistently better — 50-70% symptom reduction is typical — and third-season results better still as immune tolerance continues accumulating. Patients who remain in treatment through a disappointing first season have much higher rates of meaningful long-term benefit than those who stop after year 1. Framing the first treated season as a baseline observation rather than an efficacy test helps patients persist through the normal early phase of treatment and reach the improved results that typically follow.

Sublingual immunotherapy (SLIT) reaches therapeutic dosing in 1-7 days for most protocols, compared to SCIT's 8-28 week build-up phase. IgG4 blocking antibodies become detectable at 4-8 months with SLIT compared to 3-6 months with SCIT — the slightly slower IgG4 onset with SLIT reflects its lower per-dose allergen concentration (SLIT doses must be 50-100 times higher in total volume than SCIT doses to achieve equivalent allergen delivery, per Polish Society of Allergy Position Paper, Ann Agric Environ Med 2016). In first-season clinical trials, SLIT tablets for grass pollen show approximately 20-35% symptom reduction (Durham et al., JACI 2012), slightly less than the approximately 30% average seen with SCIT in the same season. At 12 months and beyond, the efficacy gap closes substantially in head-to-head meta-analyses for commercialized single-allergen products. For practical purposes, the real-world advantage of SLIT is its ability to start immediately at home, bypassing the scheduling and build-up delays that push SCIT's first perceivable benefit further into the future.